Literature DB >> 20598611

[Normal tissue tolerance to external beam radiation therapy: liver].

B De Bari1, Y Pointreau, E Rio, X Mirabel, F Mornex.   

Abstract

The liver is a large abdominal organ in the right hypondrium. Because of its anatomical situation, it is near many abdominal PTVs as well as some lower thoracic PVTs. The liver could also be at the same time the target (for irradiation of liver metastases or primary liver tumours) and organ at risk (OAR). Radiation-induced liver disease (RILD) is radiobiologically the normal tissue complication probability (NTCP), i.e., the clinical event limiting the total dose that could be delivered. This review describes radiobiological criteria justifying the NTCP data, and recommendations for conformal 3D radiotherapy and stereotactic liver irradiation. Copyright (c) 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598611     DOI: 10.1016/j.canrad.2010.02.013

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

Review 1.  Dose to organ at risk and dose prescription in liver SBRT.

Authors:  Rives Michel; Izar Françoise; Parent Laure; Modesto Anouchka; Portier Guillaume; Kirzin Sylvain
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-17

2.  Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes.

Authors:  Max Seidensticker; Ricarda Seidensticker; Konrad Mohnike; Christian Wybranski; Thomas Kalinski; Sebastian Luess; Maciej Pech; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2011-04-17       Impact factor: 3.481

3.  Hepatobiliary scintigraphy allows the evaluation of short-term functional toxicity of liver stereotactic body radiotherapy: Results of a pilot study.

Authors:  Berardino De Bari; Thomas Breuneval; Michele Zeverino; Sarah Godin; Letizia Deantonio; Christine Geldhof; Jean Bourhis; Nicklaus Schaefer; Raphaël Moeckli; John Prior; Mahmut Ozsahin
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.